2.02

6.05% -0.13

After Hours: 2.08 0.06 +2.97%

Tempest Therapeutics Inc (TPST)

Overview News Price History Option Chain Financials Why TPST Down? Discussions Forecast Stock Split

Tempest Therapeutics Inc stock is traded at $2.02, with a volume of 234.98K. It is down -6.05% in the last 24 hours and up +27.04% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Previous Close:

$2.15

Open:

$2.13

24h Volume:

234.98K

Relative Volume:

1.20

Market Cap:

$28.97M

Revenue:

Net Income/Loss:

$-26.26M

P/E Ratio:

-0.2955

EPS:

-6.8353

Net Cash Flow:

$-26.82M

1W Performance:

+16.09%

1M Performance:

+27.04%

6M Performance:

-57.65%

1Y Performance:

-39.43%

1-Day Range:

$1.94

$2.1499

1-Week Range:

$1.74

$2.18

52-Week Range:

$1.20

$6.115

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name

Tempest Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

415-798-8589

Address

2000 SIERRA POINT PARKWAY, BRISBANE

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

TPST's Discussions on Twitter

Compare TPST vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TPST Tempest Therapeutics Inc	2.02	30.84M	0	-26.26M	-26.82M	-6.8353
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-26	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Feb-08-24	Initiated	Jefferies	Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

08:32 AM

After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan

Apr 29, 2026

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - Sahm

Apr 29, 2026

Apr 25, 2026

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN

Apr 25, 2026

Apr 24, 2026

Tempest Therapeutics stock falls after $4.25 million direct offering - MSN

Apr 24, 2026

Apr 23, 2026

Tempest achieves manufacturing milestone for CAR-T therapy By Investing.com - Investing.com India

Apr 23, 2026

Apr 22, 2026

Tempest Therapeutics provides update on development of TPST-2003 - TipRanks

Apr 22, 2026

Tempest Therapeutics (TPST) Advances Dual-Targeting CAR-T Therap - GuruFocus

Apr 22, 2026

Tempest achieves manufacturing milestone for CAR-T therapy - Investing.com

Apr 22, 2026

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - GlobeNewswire

Apr 22, 2026

Apr 20, 2026

Tempest Therapeutics (TPST) Stock: Why Spinoff Value (Tick Down) 2026-04-20Trending Buy Opportunities - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 17, 2026

TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill

Apr 17, 2026

Apr 15, 2026

Tempest Therapeutics names Andrew Fang head of business development By Investing.com - Investing.com India

Apr 15, 2026

Apr 14, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - Bitget

Apr 14, 2026

Tempest Therapeutics names Andrew Fang head of business development - Investing.com

Apr 14, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business - GlobeNewswire

Apr 14, 2026

Apr 13, 2026

Tempest Therapeutics(TPST) Stock Options Chain | Quotes & News - Moomoo

Apr 13, 2026

Apr 12, 2026

Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN

Apr 12, 2026

Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan

Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan

Apr 10, 2026

Buyout Rumor: What is Stran Company Incs revenue forecast2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn

Apr 10, 2026

New Strong Buy Stocks for April 10th - The Globe and Mail

Apr 10, 2026

Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29%Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La

Apr 10, 2026

[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan

Apr 10, 2026

Apr 03, 2026

Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors - marketscreener.com

Apr 03, 2026

Apr 02, 2026

Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan

Apr 02, 2026

Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan

Apr 02, 2026

Versant funds report lower Tempest Therapeutics (TPST) ownership levels - Stock Titan

Apr 02, 2026

Biopharmaceutical company Tempest Therapeutics Inc (TPST) recently filed a prospectus with the U.S. Securities and Exchange Commission, planning to issue up to approximately 2.8 million common shares through resale, including related warrants. - Bitget

Apr 02, 2026

According to a filing submitted to the US Securities and Exchange Commission (SEC), Tempest Therapeutics Inc. will not receive any proceeds from the sale of the company's shares by selling shareholders. - Bitget

Apr 02, 2026

Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail

Apr 01, 2026

Tempest Therapeutics | UPLOAD: Others - Moomoo

Apr 01, 2026

Mar 31, 2026

H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $11 - moomoo.com

Mar 31, 2026

TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView — Track All Markets

Mar 31, 2026

Mar 30, 2026

According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock. - Bitget

Mar 30, 2026

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet

Mar 30, 2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update - bitget.com

Mar 30, 2026

Tempest reports year end 2025 financial results and provides business update - marketscreener.com

Mar 30, 2026